Pelthos (PTHS) Q2 2026 Earnings Call Transcript

Pelthos Therapeutics reported Q2 2026 ZELSUVMI net product revenue of $15.4M, up 45% sequentially (from $10.7M in Q1), driven by a 48% rise in prescribed units to 11,925 and growth in unique prescribers to 4,571. The quarter included a $0.9M API inventory write-off and a $5.3M non-recurring sales-based milestone payment, leaving adjusted EBITDA at -$5.7M and net loss at -$23.4M; cash was $24.2M as of June 30 and the company drew $30M of a $50M term loan (with potential access to an additional $10M). Management reiterated GTN performance at 29.6% (vs 29.1% in Q1) and expects GTNs to move into the mid-30% range, while preparing XEPI (launch Q1 2027) and Xeglyze (launch Q3 2027) using existing infrastructure.

Analysis

Near term, this is less a “growth story” than a proof-of-life story for a tiny commercial platform: if weekly demand stays stable through back-to-school, the stock can keep working because the market has been pricing this like a one-product launch with fragile channel economics. The important second-order signal is the rise in repeat writers and refills; that shifts the revenue mix from one-and-done prescriptions toward a more durable base, which should mechanically lower sales volatility and improve visibility into the next two quarters.

The hidden bear case is still financing and trust. Cash plus the term loan may cover the launch bridge, but the balance sheet is not yet self-funding, and the quality-control write-off plus the accounting restatement raise execution risk exactly where investors usually pay up for “commercial traction.” A bad read-through would be any deceleration in new prescribers or another manufacturing blemish; either would force the market to reprice the equity as a dilutive funding story rather than a launch winner.

Over 1-3 months, the key catalyst is whether access broadens without sacrificing GTN too aggressively. If the company can convert the pending plan and keep scripts flat-to-up into autumn, the multiple can expand even without a revenue beat; if not, the market will likely fade the Q2 print as seasonal and discount the 2027 pipeline. Over 6-18 months, the real upside is operating leverage from reusing the same field force across XEPI/Xeglyze, but that only matters if current commercialization proves it can sustain a repeat-prescription flywheel.

Consensus may be underestimating how much the current traction is being driven by actual physician behavior rather than channel stuffing: inventory days are low, and that matters. But consensus may also be overestimating how quickly this becomes a clean, high-quality compounding story; the step-up inventory, GTN drift, and need for more access contracts mean margins and cash conversion are still moving targets.

Key Decisions for Investors

• Tactically long PTHS for 2-6 weeks into back-to-school data, but size it as a trading position only; thesis works if weekly prescriptions hold near recent levels and repeat writers keep rising. Falsify if July/August-style volatility turns into a sustained drop below the recent weekly run-rate.
• Use a call spread on PTHS rather than outright stock if liquidity allows: the setup is for a squeeze on stable demand, but dilution risk limits upside beyond the next print. Best entry is after any post-call drift, not on strength.
• If you want lower company-specific risk, pair long PTHS vs short XBI over 1-3 months. You are betting that a real commercial launch with repeat demand outperforms an index that still contains many pre-revenue names with no visible catalyst.
• Watch HRZN as the financing overhang proxy rather than a primary long. Any incremental borrowing or tighter lender language would be a negative read-through for PTHS equity because it signals the company still needs outside capital to bridge to 2027.
• Set a hard alert on three falsifiers: weekly scripts rolling over for 3+ consecutive weeks, GTN failing to move toward the low/mid-30s, or another inventory/quality issue. Any one of those argues for exiting longs and waiting for cleaner evidence.